Drug firm accused of 'appalling deception on a grand scale' A pharmaceutical company has been accused of "appalling deception on a grand scale" after surreptitiously attempting to market prostate cancer drugs to doctors.
Astellas UK has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) over "serious breaches" of the trade group’s code of practice.
The actions relate to an event held by the company in 2014, when more than 100 doctors were invited to an “educational event” in Milan to share their expertise about prostate cancer.
In fact, an investigation found that doctors were chosen because they had limited knowledge of the sector, in the hope they would be persuaded to prescribe Xtandi – a new prostate cancer drug. The Daily Telegraph
No comments:
Post a Comment